You are here

Lumoxiti Injection Approved for Hairy Cell Leukemia

Cleared for Adults with Relapsed or Refractory Disease

Lumoxiti injection (moxetumomab pasudotox-tdfk, Astra Zeneca) has been approved to treat certain instances of relapsed or refractory "hairy cell" leukemia (HCL) in adults. The new drug is the latest addition to a novel class of drugs called CD22-directed cytotoxins to treat HCL, the FDA announced. The drug was approved for adults who have had at least two prior therapies for the disease.

Lumoxiti was evaluated in a clinical study of 80 people who had been treated previously for HCL. The most common side effects included injection-related reactions, swelling, nausea, fatigue, headache, fever, constipation, anemia, and diarrhea.

The drug's label includes a boxed warning of increased risk for capillary leak syndrome, and also notes an increased risk of hemolytic uremic syndrome. Breastfeeding women should not take the drug.

Source: U.S. News & World Report, September 13, 2018

More Headlines

Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection
Hope For Patients With Highly Aggressive Form of AML
Oncology Therapy for Adult and Pediatric Tumors With a Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene Fusion
First Hedgehog Pathway Inhibitor Approved for AML in Adults Aged 75 and Older
Gene Therapy Granted Regenerative Medicine, Fast Track Designations